Departments of Urology.
Scientific research and foreign affairs, Chongqing University Three Gorges Hospital, Chongqing, China.
Anticancer Drugs. 2023 Jan 1;34(1):144-154. doi: 10.1097/CAD.0000000000001393. Epub 2022 Oct 16.
Long noncoding RNA taurine-upregulated gene1 (TUG1) has been reported to be implicated in the chemo-resistance of bladder cancer. Hence, this study aimed to survey regulatory mechanism by which TUG1 regulates the chemo-resistance of bladder cancer cells to doxorubicin (DOX). Relative expression of TUG1, miR-582-5p, and karyopherin alpha 2 (KPNA2) was detected by qRT-PCR. The viability and proliferation of DOX-resistant bladder cancer cells were determined by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay. Protein levels were measured by western blot analysis. The apoptosis, migration, and invasion of DOX-resistant bladder cancer cells were determined by flow cytometry or transwell assays. The relationship between TUG1 or KPNA2 and miR-582-5p was verified by dual-luciferase reporter assay. TUG1 and KPNA2 were upregulated while miR-582-5p was downregulated in resistant bladder cancer tissues and cells. TUG1 inhibition elevated cell chemo-sensitivity, facilitated cell apoptosis, and curbed proliferation, migration, invasion, and autophagy of DOX-resistant bladder cancer cells. Also, TUG1 acted as a sponge for miR-582-5p, and miR-582-5p inhibitor reversed TUG1 knockdown-mediated influence on DOX chemo-sensitivity and malignant behaviors in DOX-resistant bladder cancer cells. Furthermore, miR-582-5p targeted KPNA2, and KPNA2 overexpression counteracted the inhibitory impact of miR-582-5p mimic on DOX chemo-resistance and malignant behaviors in DOX-resistant bladder cancer cells. Additionally, TUG1 silencing inactivated the PI3K/AKT pathway through sponging miR-582-5p. TUG1 sponged miR-582-5p to increase KPNA2 expression and activated the KPNA2/PI3K/AKT pathway, thereby elevating DOX chemo-resistance and malignant behaviors in bladder cancer cells.
长链非编码 RNA 牛磺酸上调基因 1(TUG1)已被报道与膀胱癌的化疗耐药有关。因此,本研究旨在调查 TUG1 调节膀胱癌细胞对多柔比星(DOX)化疗耐药的调控机制。通过 qRT-PCR 检测 TUG1、miR-582-5p 和核孔蛋白α2(KPNA2)的相对表达。通过 3-(4,5-二甲基-2-噻唑基)-2,5-二苯基-2-H-四唑溴盐(MTT)测定法测定 DOX 耐药膀胱癌细胞的活力和增殖。通过 Western blot 分析测定蛋白水平。通过流式细胞术或 Transwell 测定法测定 DOX 耐药膀胱癌细胞的凋亡、迁移和侵袭。通过双荧光素酶报告基因测定验证 TUG1 或 KPNA2 与 miR-582-5p 的关系。在耐药膀胱癌组织和细胞中,TUG1 和 KPNA2 上调,而 miR-582-5p 下调。TUG1 抑制提高了细胞化疗敏感性,促进了细胞凋亡,并抑制了 DOX 耐药膀胱癌细胞的增殖、迁移、侵袭和自噬。此外,TUG1 作为 miR-582-5p 的海绵,miR-582-5p 抑制剂逆转了 TUG1 敲低对 DOX 耐药膀胱癌细胞化疗敏感性和恶性行为的影响。此外,miR-582-5p 靶向 KPNA2,而 KPNA2 过表达抵消了 miR-582-5p 模拟物对 DOX 耐药和 DOX 耐药膀胱癌细胞恶性行为的抑制作用。此外,TUG1 沉默通过海绵吸附 miR-582-5p 使 PI3K/AKT 通路失活。TUG1 吸附 miR-582-5p 以增加 KPNA2 表达并激活 KPNA2/PI3K/AKT 通路,从而提高膀胱癌细胞的 DOX 化疗耐药性和恶性行为。